聚腺苷二磷酸核糖聚合酶抑制剂作为卵巢癌一线维持治疗的划时代策略：系统评价和荟萃分析。
PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis.
机构信息
Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Biochemistry and Molecular Biology, Basic Medicine College, Shanxi Medical University, Taiyuan, China.
出版信息
Cancer Invest. 2022 Nov;40(10):889-900. doi: 10.1080/07357907.2022.2088780. Epub 2022 Jul 18.
BACKGROUND
To illustrate the accurate location of Poly-ADP-ribose polymerase inhibitor (PARPi) as the first-line maintenance therapy in advanced ovarian cancer (AOC).
METHODS
Search for eligible studies and calculate clinical outcomes.
RESULTS
PARPi as a first-line maintenance treatment significantly prolonged the BRCAmut population and the homologous recombination deficiency (HRD) positive population.
CONCLUSION
PARPi as first-line maintenance therapy significantly improves the progression-free survival in AOC, especially in the BRCAmut and HRD positive populations. PARPi has been becoming the standard first-line maintenance therapy for AOC.
背景
为了阐明聚 ADP-核糖聚合酶抑制剂（PARPi）作为一线维持治疗在晚期卵巢癌（AOC）中的精确位置。
方法
搜索合格的研究并计算临床结果。
结果
PARPi 作为一线维持治疗显著延长了 BRCA 突变人群和同源重组缺陷（HRD）阳性人群的无进展生存期。
结论
PARPi 作为一线维持治疗显著改善了 AOC 的无进展生存期，尤其是在 BRCA 突变和 HRD 阳性人群中。PARPi 已成为 AOC 的标准一线维持治疗。
Zotero 插件